EP2034838A4 - Neuartige verbindungen - Google Patents

Neuartige verbindungen

Info

Publication number: EP2034838A4
Authority: EP; European Patent Office
Prior art keywords: novel compounds; novel; compounds
Prior art date: 2006-06-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP07798622A

Other languages

English (en)

French (fr)

Other versions

EP2034838A2 (de

Inventor

Mauro Corsi

Isidore Faiferman

Emilio Merlo-Pich

Emiliangelo Ratti

Paul Bryan Wren

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-16

Filing date

2007-06-15

Publication date

2012-01-04

2007-06-15 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-03-18 Publication of EP2034838A2 publication Critical patent/EP2034838A2/de

2012-01-04 Publication of EP2034838A4 publication Critical patent/EP2034838A4/de

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP07798622A 2006-06-16 2007-06-15 Neuartige verbindungen Withdrawn EP2034838A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80499306P	2006-06-16	2006-06-16
PCT/US2007/071314 WO2007147103A2 (en)	2006-06-16	2007-06-15	Novel compounds

Publications (2)

Publication Number	Publication Date
EP2034838A2 EP2034838A2 (de)	2009-03-18
EP2034838A4 true EP2034838A4 (de)	2012-01-04

Family

ID=38832896

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07798622A Withdrawn EP2034838A4 (de)	2006-06-16	2007-06-15	Neuartige verbindungen

Country Status (4)

Country	Link
US (1)	US20100144755A1 (de)
EP (1)	EP2034838A4 (de)
JP (1)	JP2009542816A (de)
WO (1)	WO2007147103A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0612026D0 (en)	2006-06-16	2006-07-26	Smithkline Beecham Corp	New use
EP2134695A4 (de) *	2007-03-14	2011-05-25	Exelixis Inc	Hemmer des hedgehog-signalweges
EP2221053A1 (de) *	2009-02-20	2010-08-25	Albert-Ludwigs-Universität Freiburg	Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
WO2015072580A1 (ja) *	2013-11-14	2015-05-21	学校法人同志社	細胞増殖促進または細胞障害抑制による角膜内皮治療薬
CN103664796A (zh) *	2013-12-06	2014-03-26	辽宁师范大学	5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法
CN103664770A (zh) *	2013-12-06	2014-03-26	辽宁师范大学	5-[2-(5-羧基-吡啶基)]-1,3-苯二羧酸的合成方法
EP3381472A4 (de)	2015-12-24	2019-07-31	The Doshisha	Arzneimittel zur behandlung oder vorbeugung von durch tgf-signale verursachten störungen und verwendung davon
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG11202003035SA (en)	2017-10-05	2020-04-29	Fulcrum Therapeutics Inc	Use of p38 inhibitors to reduce expression of dux4
JPWO2020184605A1 (de) *	2019-03-12	2020-09-17
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
CN116635377A (zh) *	2020-12-25	2023-08-22	四川海思科制药有限公司	己酮糖激酶抑制剂及其用途
CN113501762A (zh) *	2021-07-27	2021-10-15	南京硕达生物科技有限公司	一种2,6-二氟苯胺的工业化生产方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050203109A1 (en) *	2000-10-23	2005-09-15	Smithkline Beecham Corporation	Novel Compounds
WO2006104915A2 (en) *	2005-03-25	2006-10-05	Glaxo Group Limited	8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4603268B2 (ja) *	2002-04-19	2010-12-22	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規化合物
UY29439A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos

2007
- 2007-06-15 EP EP07798622A patent/EP2034838A4/de not_active Withdrawn
- 2007-06-15 US US12/305,077 patent/US20100144755A1/en not_active Abandoned
- 2007-06-15 JP JP2009530691A patent/JP2009542816A/ja active Pending
- 2007-06-15 WO PCT/US2007/071314 patent/WO2007147103A2/en active Application Filing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050203109A1 (en) *	2000-10-23	2005-09-15	Smithkline Beecham Corporation	Novel Compounds
WO2006104915A2 (en) *	2005-03-25	2006-10-05	Glaxo Group Limited	8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS

Also Published As

Publication number	Publication date
JP2009542816A (ja)	2009-12-03
WO2007147103A3 (en)	2008-11-13
US20100144755A1 (en)	2010-06-10
WO2007147103A2 (en)	2007-12-21
EP2034838A2 (de)	2009-03-18

Publication	Publication Date	Title
EP2034838A4 (de)	2012-01-04	Neuartige verbindungen
EP2032142A4 (de)	2010-07-21	Neuartige verbindungen
EP1981596A4 (de)	2010-09-01	Neue verbindungen
GB0603550D0 (en)	2006-04-05	Novel compounds
EP1981900A4 (de)	2011-01-26	Neuartige verbindungen
GB0609962D0 (en)	2006-06-28	Novel compounds
GB0605462D0 (en)	2006-04-26	Novel compounds
GB0602900D0 (en)	2006-03-22	Novel Compounds
GB0609117D0 (en)	2006-06-21	Novel compounds
GB0609963D0 (en)	2006-06-28	Novel compounds
EP2031965A4 (de)	2010-06-30	Neuartige verbindungen
GB0607840D0 (en)	2006-05-31	Novel compounds
GB0607892D0 (en)	2006-05-31	Novel compounds
GB0600483D0 (en)	2006-02-22	Novel compounds
GB0609252D0 (en)	2006-06-21	Novel sytoprotective compounds
GB0608452D0 (en)	2006-06-07	Novel compounds
GB0606527D0 (en)	2006-05-10	Novel compounds
GB0603779D0 (en)	2006-04-05	Novel compounds
GB0608299D0 (en)	2006-06-07	Novel Compounds
GB0607736D0 (en)	2006-05-31	Novel compounds
GB0607529D0 (en)	2006-05-24	Novel compounds
GB0607353D0 (en)	2006-05-24	Novel Compounds
GB0606763D0 (en)	2006-05-10	Novel compounds
GB0606549D0 (en)	2006-05-10	Novel compounds
GB0608455D0 (en)	2006-06-07	Novel compounds

Legal Events

Date	Code	Title	Description
2009-02-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-03-18	17P	Request for examination filed	Effective date: 20090114
2009-03-18	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2009-03-18	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2012-01-04	A4	Supplementary search report drawn up and despatched	Effective date: 20111201
2012-01-04	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 27/02 20060101ALI20111125BHEP Ipc: A61P 25/00 20060101ALI20111125BHEP Ipc: A61K 31/519 20060101ALI20111125BHEP Ipc: A01N 43/90 20060101AFI20111125BHEP
2012-08-08	RAX	Requested extension states of the european patent have changed	Extension state: HR Payment date: 20090114
2012-11-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-12-26	18D	Application deemed to be withdrawn	Effective date: 20120703